Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Bempedoic acid / ezetimibe fixed dose combination (FDC) tablet is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver
Bempedoic acid / ezetimibe FDC tablet lowered LDL-C by 38% (placebo-corrected) and re... Biopharmaceuticals, Cardiology Daiichi Sankyo, bempedoic acid, ezetimibe, FDC tablet
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cholesterol | Heart | Liver | Pharmaceuticals | Study | Urology & Nephrology | Vytorin | Zetia